SageView Advisory Group’s Innate Pharma IPHA Stock Holding History

SageView Advisory Group’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$2	–	1479
2025 Q4	$2	Buy	+1	New	+$2	﹤0.01%	2607

Other funds holding IPHA

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

SageView Advisory Group's IPHA Position: Q1 2026 in Review

SageView Advisory Group sold out of Innate Pharma (IPHA) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

SageView Advisory Group first reported a position in IPHA in Q4 2025 and held it in 1 quarter. The position peaked at $2 in Q4 2025. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2026.

SageView Advisory Group reported no remaining Innate Pharma position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 1 Innate Pharma share in Q1 2026, an estimated $2.
SageView Advisory Group first reported a position in Innate Pharma in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Innate Pharma position peaked at $2 in Q4 2025.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.